AMENDMENTS TO THE CLAIMS:

The listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

1-183 (Canceled).

184. (New) A polypeptide of from five to 64 amino acids that inhibits the growth of a tumor cell or inhibits the growth of prostatic adenocarcinoma, wherein at least five contiguous amino acids of said polypeptide are identical to five contiguous amino acids of SEQ ID NO: 5.

185. (New) The polypeptide of claim 184, wherein said polypeptide comprises the amino acid sequence defined in SEQ ID NO.:5.

186. (New) The polypeptide of claim 184, wherein said polypeptide consists of the amino acid sequence defined in SEQ ID NO.:5

187. (New) The polypeptide of claim 184, wherein said polypeptide comprises amino acids no.1 to 6 of SEQ ID NO.:5.

188. (New) The polypeptide of claim 184, wherein said polypeptide is as defined in any one of SEQ ID NOS.:10 to 88.

189. (New) The polypeptide of claim 184, wherein said polypeptide is as defined in any one of SEQ ID NO.: 90, SEQ ID NO.: 91 and SEQ ID NO.: 92.

190. (New) The polypeptide of claim 184, wherein said polypeptide has at least 50% of its amino acid sequence identical to the amino acid sequence defined in SEQ ID NO.:5.

191. (New) The polypeptide of claim 190, wherein said polypeptide has at least 70% of its amino acid sequence identical to the amino acid sequence defined in SEQ ID NO.:5.

192. (New) The polypeptide of claim 191, wherein said polypeptide has at least 80% of its amino acid sequence identical to the amino acid sequence defined in SEQ ID NO.:5.

193. (New) The polypeptide of claim 192, wherein said polypeptide has at least 90% of its amino acid sequence identical to the amino acid sequence defined in SEQ ID NO.:5.

194. (New) A pharmaceutical composition comprising:

a) the polypeptide **of claim 184**; and

b) at least one of an anticancer drug and a pharmaceutically acceptable carrier.

195. (New) The pharmaceutical composition of claim 194, wherein said anticancer drug is selected from the group consisting of mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxotere, taxane, and mixtures thereof.

196. (New) The pharmaceutical composition of claim 194, further comprising a time-release means selected from the group consisting of liposomes and polysaccharides for effecting continual dosing of the composition.

197. (New) A method of treating a patient having a tumor or having prostatic adenocarcinoma, the method comprising administering the pharmaceutical composition **of claim 194.**

198. (New) A polypeptide which inhibits the growth of a tumor cell or inhibits the growth of prostatic adenocarcinoma, said polypeptide having at least 40% of its

amino acid sequence being identical to the amino acid sequence defined in SEQ ID NO.:5.

199. (New) The polypeptide of claim 198, wherein said polypeptide has at least 50% of its amino acid sequence identical to the amino acid sequence defined in SEQ ID NO.:5.

200. (New) The polypeptide of claim 199, wherein said polypeptide has at least 70% of its amino acid sequence identical to the amino acid sequence defined in SEQ ID NO.:5.

201. (New) The polypeptide of claim 200, wherein said polypeptide has at least 80% of its amino acid sequence identical to the amino acid sequence defined in SEQ ID NO.:5.

202. (New) The polypeptide of claim 201, wherein said polypeptide has at least 90% of its amino acid sequence identical to the amino acid sequence defined in SEQ ID NO.:5.

203. (New) A pharmaceutical composition comprising:

a) the polypeptide **of claim 198**; and

b) at least one of an anticancer drug and a pharmaceutical carrier.

204. (New) The pharmaceutical composition of claim 203, wherein said composition comprises an anticancer drug selected from the group consisting of mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxotere, taxane, and mixtures thereof.

205. (New) The pharmaceutical composition of claim 203, further comprising a time-release means selected from the group consisting of liposomes and polysaccharides for effecting continual dosing of the composition.

206. (New) A method of treating a patient having a tumor or having prostatic adenocarcinoma, the method comprising administering the pharmaceutical composition **of claim 203**.

207. (New) A pharmaceutical composition comprising;

a) a polypeptide consisting of the amino acid sequence defined in SEQ ID NO.:5, and

b) at least one of an anticancer drug and a pharmaceutical carrier.

208. (New) The pharmaceutical composition of claim 207 wherein the polypeptide is used in a dosage range from about 100 nanograms/kg/day to about 4 milligrams/kg/day.

209. (New) The pharmaceutical composition of claim 207, wherein said anticancer drug is selected from the group consisting of mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxotere, taxane, and mixtures thereof.

210. (New) The pharmaceutical composition of claim 207, further comprising a time-release means selected from the group consisting of liposomes and polysaccharides for effecting continual dosing of the composition.

211. (New) A method of treating a patient having a tumor or having prostatic adenocarcinoma, the method comprising administering the pharmaceutical composition **of claim 207**.

212. (New) A pharmaceutical composition comprising;

a) the polypeptide of **claim 187**; and

b) at least one of an anticancer drug and a pharmaceutically acceptable carrier.

213. (New) A method of treating a patient having a tumor or having prostatic adenocarcinoma, the method comprising administering the pharmaceutical composition **of claim 212**.

214. (New) A pharmaceutical composition comprising:

a) a polypeptide comprising SEQ ID NO.:5 provided that said polypeptide is not as defined in SEQ ID NO.:1, and

b) at least one of an anticancer drug and a pharmaceutically acceptable carrier.

215. (New) The pharmaceutical composition of claim 214 wherein the polypeptide is used in a dosage range from about 100 nanograms/kg/day to about 4 milligrams/kg/day.

216. (New) The pharmaceutical composition of claim 214, wherein said anticancer drug is selected from the group consisting of mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxotere, taxane, and mixtures thereof.

217. (New) The pharmaceutical composition of claim 214 further comprising a time-release means selected from the group consisting of liposomes and polysaccharides for effecting continual dosing of the composition.

218. (New) A method of treating a patient having a tumor or having prostatic adenocarcinoma, the method comprising administering the pharmaceutical composition **of claim 214**.

219. (New) A polypeptide comprising at least two repetitions of the amino acid sequence defined in SEQ ID NO.:5.

220. (New) A pharmaceutical composition comprising:

a) the polypeptide of **claim 219**, and

b) at least one of an anticancer drug and a pharmaceutically acceptable carrier.

221. (New) A method of treating a patient having a tumor or having prostatic adenocarcinoma, the method comprising administering the pharmaceutical composition **of claim 220**.

222. (New) A pharmaceutical composition comprising;

a) the polypeptide **of claim 185**; and

b) at least one of an anticancer drug and a pharmaceutically acceptable carrier.

223. (New) A method of treating a patient having a tumor or having prostatic adenocarcinoma, the method comprising administering the pharmaceutical composition **of claim 222**.